Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sleep Apnea, Obstructive, Tonsillectomy, Adenoidectomy, Postoperative Complications
Interventions: Caffeine, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Months to 18 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Placebo, Trivalent Inactivated Influenza; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Rupture of Anterior Cruciate Ligament
Interventions: Somatropin, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Decompression Sickness
Interventions: Sodium Chloride 0.9% Inj pre-exposure, Sodium Chloride 0.9% Inj post-exposure, Recombinant human plasma gelsolin pre-exposure, Recombinant human plasma gelsolin post-exposure, Hyperbaric chamber; Drug · Other
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anthrax
Interventions: Normal Saline for Injection, MDX1303; Drug · Biological
Lead sponsor: PharmAthene, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 38
States / cities: Birmingham, Alabama • Bakersfield, California • Cerritos, California + 33 more

Conditions: Premature Birth
Interventions: Betamethasone - ACTIVE, Normal Saline - PLACEBO; Drug · Other
Lead sponsor: Pediatrix; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more

Conditions: COVID-19
Interventions: Placebo, Remdesivir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 35 more

Conditions: Hidradenitis Suppurativa
Interventions: etanercept; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obesity
Interventions: exenatide, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Peoria, Arizona • Tucson, Arizona • Santa Ana, California + 11 more

Conditions: Multiple Trauma
Interventions: Omega-3, Placebo; Dietary Supplement
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Postoperative Pain, Postoperative Nausea and Vomiting
Interventions: Ropivacaine, Placebo, Transversus Abdominis Plane Block; Drug · Other · Procedure
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 40
States / cities: Downy, California • Fountain Valley, California • Fullerton, California + 37 more

Conditions: Covid19
Interventions: Placebo, Montelukast; Other · Drug
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 109
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Conditions: Parkinson Disease
Interventions: GM1 ganglioside, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 39 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Migraine
Interventions: Ketorolac, intranasal, Ketorolac, intravenous, Placebo, intravenous, Placebo, intranasal; Drug
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking Cessation
Interventions: Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 19 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 56
States / cities: Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 28
States / cities: Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more

Conditions: Virus Diseases
Interventions: Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 5
States / cities: Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more

Conditions: Healthy Volunteers
Interventions: Botulism Antitoxin Bivalent (Equine) Types A and B, Botulism Antitoxin Heptavalent (Equine) Types A-G; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Loma Linda, California • Yakima, Washington

Conditions: Autism Spectrum Disorder
Interventions: Sulforaphane, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 3 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: RSV Infection
Interventions: RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 59 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions: Dexmedetomidine, 0.9% Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).

Th1 Response to Influenza: Aging and Vaccine Efficacy

Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears

Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

Adaptive COVID-19 Treatment Trial (ACTT)

Treatment of Hidradenitis Suppurativa Using Etanercept

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients

Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

GM1 Ganglioside Effects on Parkinson's Disease

Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children

Smoking Cessation Study In Healthy Adolescent Smokers

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion